Clinical and Functional Phenotypes of Chronic Obstructive Pulmonary Disease, the Effect on the Severity of the Disease and Prognostic Value in Assessing the Risk of Disease Progression

Cover Page
  • Authors: Karnaushkina M.A.1, Fedosenko S.V.2, Sazonov A.E.3, Petrov V.A.2, Arutyunova A.B.4, Maksimova M.A.5, Ogorodova L.M.2, Deev I.A.2, Kulikov E.S.2
  • Affiliations:
    1. I.M. Sechenov First Moscow State Medical University
    2. Siberian State Medical University
    3. M.V. Lomonosov Moscow State University
    4. Clinical hospital of Central union of Russia
    5. Policlinic 2 of Ministry of Economic Development of Russia
  • Issue: Vol 71, No 6 (2016)
  • Section: PULMONOLOGY: CURRENT ISSUES
  • URL: https://vestnikramn.spr-journal.ru/jour/article/view/715
  • DOI: https://doi.org/10.15690/vramn715
  • Cite item

Abstract


Background: Chronic obstructive pulmonary disease (COPD) is characterized by progressive limitation of airflow rate, hyperergic inflammatory response of the respiratory tract, and systemic manifestations. Prognosis of the disease depends on the severity of these pathogenetic components. FEV1 which characterizes the speed limit airflow do not allow predicting the rate of COPD progression.

Aims: comparison of the prognostic significance of such clinical parameters as frequency of exacerbations and the development of comorbid diseases to assess the nature of COPD progression by using different classification approaches.

Materials and methods: The prospective comparative study included 98 patients with COPD. In the framework of the study protocol, 2 visits were required when a practitioner recruited patients who met inclusion/exclusion criteria, obtained the signed informed consent, collected the anamnestic data, and performed basic procedures of the study: spirometry, 6-minute stepper test, assessment of dyspnea on questionnaire mMRC, body plethysmography, lung diffusion capacity study, dopplerechocardiography, tomography of the chest. Visit 2 was conducted in 12 months after the first one to assess the dynamics of the disease. The dynamics of the disease was considered negative if, upon repeated examination, the patient was referred to the group with more severe COPD.

Results: Our study demonstrates that comprehensive assessment of such factors as the frequency of COPD exacerbations in the preceding 12 months and the presence of comorbid diseases in a patient is reasonable for assessment of disease severity and determination of disease prognosis. At the same time the frequency of COPD exacerbations as one of the evaluated factors is most strongly associated with disease progression.

Conclusions: Thus, a practitioner is recommended to use the proposed additional clinical criteria to assess the severity and degree of progression of COPD.


M. A. Karnaushkina

I.M. Sechenov First Moscow State Medical University

Email: kar3745@yandex.ru
ORCID iD: 0000-0002-8791-2920

Moscow, Russian Federation

S. V. Fedosenko

Siberian State Medical University

Author for correspondence.
Email: s-fedosenko@mail.ru
ORCID iD: 0000-0001-6655-3300

Russian Federation

Tomsk, Russian Federation

A. E. Sazonov

M.V. Lomonosov Moscow State University

Email: sazonov@rector.msu.ru
ORCID iD: 0000-0001-8611-5770

Moscow, Russian Federation

V. A. Petrov

Siberian State Medical University

Email: vyacheslav.a.petrov@mail.ru
ORCID iD: 0000-0002-5205-9739

Tomsk, Russian Federation

A. B. Arutyunova

Clinical hospital of Central union of Russia

Email: al1408@bk.ru
Moscow, Russian Federation

M. A. Maksimova

Policlinic 2 of Ministry of Economic Development of Russia

Email: may67@mail.ru

Moscow, Russian Federation

L. M. Ogorodova

Siberian State Medical University

Email: lm-ogorodova@mail.ru
ORCID iD: 0000-0002-2962-1076

Tomsk, Russian Federation

I. A. Deev

Siberian State Medical University

Email: ivandeyev@yandex.ru
ORCID iD: 0000-0002-4449-4810

Tomsk, Russian Federation

E. S. Kulikov

Siberian State Medical University

Email: Evgeny.s.kulikov@gmail.com
ORCID iD: 0000-0002-0088-9204

Tomsk, Russian Federation

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Internet]. Updated 2015 Apr; cited 2016 Aug 15. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf.
  2. Celli BR, Cote CG, Lareau SC, Meek PM. Predictors of Survival in COPD: more than just the FEV1. Respir Med. 2008;102 Suppl 1:S27–35. doi: 10.1016/S0954-6111(08)70005-2.
  3. Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181. doi: 10.1186/1741-7015-11-181.
  4. Jones PW, Chen WH, Wilcox TK, et al. Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest. 2011;139(6):1388–1394. doi: 10.1378/chest.10-1240.
  5. Halpin DM, Decramer M, Celli B, et al. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:653–661. doi: 10.2147/COPD.S34186.
  6. Jenkins CR, Celli B, Anderson JA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39(1):38–45. doi: 10.1183/09031936.00194610.
  7. Kostikas K, Bakakos P, Papiris S, et al. Systemic biomarkers in the evaluation and management of COPD patients: are we getting closer to clinical application? Curr Drug Targets. 2013;14(2):177–191. doi: 10.2174/1389450111314020005.
  8. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest. 2011;139(1):165–173. doi: 10.1378/chest.10-1252.
  9. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185. doi: 10.1183/09031936.00128008.
  10. Cavailles A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454–475. doi: 10.1183/09059180.00008612.
  11. Agusti A, Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2012;9(2):43–46. doi: 10.1513/pats.201108-050MS.
  12. Agusti A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(5):507–513. doi: 10.1164/rccm.201103-0405PP.
  13. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010;65(10):930–936. doi: 10.1136/thx.2009.130260.
  14. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J. 1993;(6 Suppl 16):5–40. doi: 10.1183/09041950.005s1693.
  15. Berger M, Haimowitz A, Van Tosh A, et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 1985;6(2):359–365. doi: 10.1016/s0735-1097(85)80172-8.
  16. Куницына Ю.Л., Шмелев Е.И. Противовоспалительная терапия при ХОБЛ // Пульмонология. — 2003. — №2 — С. 111–116. [Kunitsina YuL, Shmelev EI. Protivovospalitel’naya terapiya pri KhOBL. Pul’monologiya. 2003;(2):111–116. (In Russ).]

Views

Abstract - 64

PDF (Russian) - 18

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies